MARATTO

preprint

Clinical Characteristics and Outcome of Invasive Mould Sinusitis in Children with Hematological Malignancies

2024Open accessHelwan University

Abstract

Background: Pediatric patients with hematologic malignancies are susceptible to invasive mould sinusitis (IMS). IMS is a rare entity that requires careful attention and prompts management due to its high mortality. Methods: This is a retrospective analysis of pediatric patients with hematological malignancies treated at Children Cancer Hospital Egypt through the period from 2008 till 2016 with proven IMS. Results: Thirty-four patients were diagnosed with IMS. Five 5(15%) patients had an invasive rhino-cerebral fungal disease. Mucormycosis were isolated in 17(50%) patients, Aspergillosis in 13 (38%) patients, and mixed fungal in 4 (12%) patients. Sinuses were the only localized site in (45%). Extra-nasal spread was reported in 20 patients; Sino-pulmonary in 12(35%), Sino-cerebral in 5(15%), and Sino-orbital in 2(5%) patients. Combined antifungal therapy with surgical debridement was done in 59% of patients with a better outcome when compared to those who received only medical antifungal treatment (P = 0.01). The overall mortality rate at week 12 was 35% (12 patients), and IMS attributable mortality was 20% (7 patients). IMS with cerebral extension carried the highest mortality rate for both 12-week all-cause (p=0.04) and fungal-attributable (P=0.01) mortality. Conclusions: Pediatric patients with hematologic malignancies are susceptible to invasive mould sinusitis (IMS). Surgical debridement, combined with antifungal therapy, improves outcomes among those patients. IMS patients with cerebral extension had a higher risk of mortality.

Research topics

  • Antifungal resistance and susceptibility
  • Sinusitis and nasal conditions
  • Pneumocystis jirovecii pneumonia detection and treatment

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.22541/au.170666483.36204745/v1

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.